Nilüfer Onak KANDEMİR, Burak BAHADIR, Banu Doğan GÜN, Gamze YURDAKAN, Nimet KARADAYI, Şükrü Oğuz ÖZDAMAR

CD10 expression in urothelial bladder carcinomas: staining patterns and relationship with pathologic parameters*

CD10 is a cell surface metalloprotease that inactivates various bioactive neuropeptides. CD10 has been suggested as a useful prognostic marker for urothelial carcinoma, but there are only a few studies of CD10 in urothelial tumors and they have shown varying results. The aims of this study were to investigate the expression of CD10 in urothelial bladder carcinomas and to clarify its association with pathologic parameters. Materials and methods: A total of 50 urothelial bladder carcinomas were selected from archival material. All cases were reevaluated histopathologically and graded according to the WHO/ISUP 1998 classification. The TNM system was used for their pathological staging. CD 10 immunohistochemical staining was performed on one representative tissue block for each case. Results: 35 of the 50 (70%) tumors showed positive CD10 immunostaining. We found a statistically significant difference in terms of CD10 extent between low grade and high grade tumors. No association was detected between CD10 expression and other pathologic parameters. No relationship was found between CD10 expression and tumor size, lymphovascular invasion, or pathological stage. Conclusion: According to our findings, high grade carcinomas showed a wider CD10 expression than that in low grade carcinomas. CD10 may play an important role in the progression and differentiation of bladder urothelial carcinomas.

Anahtar Kelimeler:

Key words: Bladder, papillary urothelial carcinoma, CD10, immunohistochemistry

CD10 expression in urothelial bladder carcinomas: staining patterns and relationship with pathologic parameters*

Keywords:

Key words: Bladder, papillary urothelial carcinoma, CD10, immunohistochemistry,

PDF

___

Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D et al.. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Invest 2000; 106: 1399–1407.
Dai J, Shen RQ, Sumitomo M, Goldberg JS, Geng Y, Navarro D et al. Tumor suppressive effects of neutral endopeptidase in androgen-independent prostate cancer. Clin Cancer Res 2001; 7: 1370-1377.
Ganju RK, Sunday ME, Tsarwhas DG, Card A, Shipp MA. CD10/ NEP in non-small cell lung carcinomas: relationship to cellular proliferation. J Clin Invest 1994; 94 (5): 1784-1791.
Ogawa H, Iwaya K, Izumi M, Kroda M, Serizawa H, Koyanagi Y et al. Expression of CD10 by stromal cells during colorectal tumor development. Hum Pathol 2002; 33: 806-811.
Iwaya K, Ogawa H, Izumi M, Kuroda M, Serizawa H, Koyanagi Y et al. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. Virchows Arch 2002; 440: 589-593.
Kanitakis J, Narvaez D, Claudy A. Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin. Melanoma Res 2002; 12: 241–244.
Bircan S, Candir O, Kapucuoglu N. CD10 expression in urothelial bladder carcinomas: A pilot study. Urol Int 2006; 77: 107-113.
Murali R, Delprado W. CD10 ımmunohistochemical staining in urothelial neoplasms. Am J Clin Pathol 2005; 124: 371-379.
Koiso K, Akaza H, Ohtani M, Miyanaga N, Aoyagi K.A new tumor marker for bladder cancer. Int J Urol 1994; 1: 33-36.
Chu PG, Arber DA, Weiss LM, Chang KL. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod Pathol 2001; 14(5): 465–71.
Kim MK, Kim S. Immunhistochemical profile of common epithelial neoplasms arising in the kidney. Appl Immunohistochem Mol Morphol 2002; 154: 77–82.
Simon R, Jones PA, Sidransky D, Hartmann A, Schmitz- Drager BC, Helpap B et al. Genetics and predictive factors of non- invasive urothelial neoplasias. In: Eble JN, Sauter G, Epstein JI, et al, eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004:120–123. World Health Organization Classification of Tumours.
Cheng L, Neumann RM, Nehra A, Spotts BE, Weaver AL, Bostwick DG. Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. Cancer 2000; 88: 1663–1670.
Lopez-Beltran A, Sauter G, Gasser T, Hartmann A, Schmitz- Drager BC, Helpap B et al. Infiltrating urothelial carcinoma. In: Eble JN, Sauter G, Epstein JI, et al, eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004: 93–109. World Health Organization Classification of Tumours.
Lee R, Droller MJ. The natural history of bladder cancer: implications for therapy. Urol Clin N Am 2000; 27: 1-13.